TY - JOUR
T1 - The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: A quality-assurance report on the dummy run of EORTC Phase III randomized trial 22922/10925 in Stage I-III breast cance
AU - Poortmans, Philip M. P.
AU - Venselaar, Jack L. M.
AU - Struikmans, Henk
AU - Hurkmans, Coen W.
AU - Davis, J. B.
AU - Huyskens, Dominique
AU - van Tienhoven, Geertjan
AU - Vlaun, Vernon
AU - Lagendijk, Jan J. W.
AU - Mijnheer, Ben J.
AU - de Winter, Karin A.
AU - van der Hulst, Marleen H.
AU - van den Bogaert, Walter F. C.
PY - 2001
Y1 - 2001
N2 - Purpose: To present the results of the dummy run of the European Organization for Research and Treatment of Cancer (EORTC) trial investigating the role of adjuvant internal mammary and medial supraclavicular (IM-MS) irradiation in Stage I-III breast cancer. Methods and Materials: All participating institutions were asked to produce a treatment plan without (Arm 1) and with (Arm 2) simultaneous IM-MS irradiation of 1 patient after mastectomy and of 1 patient after lumpectomy. Thirty-two dummy runs have been evaluated for compliance to protocol guidelines, with respect to treatment technique and dose prescription. Results: A number of more or less important deviations in treatment setup and prescription have been found. The dose in the IM-MS region deviated significantly from the prescribed dose in 10% of the cases for Arm 1, and in 21% for Arm 2. Assuming a true 5% 10-year survival benefit from optimal IM-MS irradiation, an increase of only 3.8% will be found due to this suboptimal dose distribution. Conclusion: In the dummy run, a number of potential systematic protocol deviations that might lead to false-negative results were detected. By providing recommendations to the participating institutions, we expect to improve the interinstitutional consistency and to promote a high quality irradiation in all institutions participating in the trial. Copyright © 2001 Elsevier Science Inc.
AB - Purpose: To present the results of the dummy run of the European Organization for Research and Treatment of Cancer (EORTC) trial investigating the role of adjuvant internal mammary and medial supraclavicular (IM-MS) irradiation in Stage I-III breast cancer. Methods and Materials: All participating institutions were asked to produce a treatment plan without (Arm 1) and with (Arm 2) simultaneous IM-MS irradiation of 1 patient after mastectomy and of 1 patient after lumpectomy. Thirty-two dummy runs have been evaluated for compliance to protocol guidelines, with respect to treatment technique and dose prescription. Results: A number of more or less important deviations in treatment setup and prescription have been found. The dose in the IM-MS region deviated significantly from the prescribed dose in 10% of the cases for Arm 1, and in 21% for Arm 2. Assuming a true 5% 10-year survival benefit from optimal IM-MS irradiation, an increase of only 3.8% will be found due to this suboptimal dose distribution. Conclusion: In the dummy run, a number of potential systematic protocol deviations that might lead to false-negative results were detected. By providing recommendations to the participating institutions, we expect to improve the interinstitutional consistency and to promote a high quality irradiation in all institutions participating in the trial. Copyright © 2001 Elsevier Science Inc.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0035312198&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/11286848
U2 - https://doi.org/10.1016/S0360-3016(00)01549-2
DO - https://doi.org/10.1016/S0360-3016(00)01549-2
M3 - Article
C2 - 11286848
SN - 0360-3016
VL - 49
SP - 1399
EP - 1408
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 5
ER -